MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription

Liang Deng,Karin A. Vallega,Shuo Zhang,Puyu Shi,Shi-Yong Sun

DOI: https://doi.org/10.1016/j.neo.2021.06.006

IF: 6.218

2021-08-01

Neoplasia

Abstract:Death receptor 4 (DR4) is a cell surface protein that is generally thought to mediate apoptosis upon binding to its ligand named TRAIL. However, its contribution to apoptosis resistance has also been reported. MET (or c-MET) gene amplification represents an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) against EGFR mutant non-small cell lung cancer (NSCLC). This study focuses on demonstrating the impact of MET inhibition on DR4 modulation in MET-amplified EGFR mutant NSCLC cell lines and the underlying mechanisms. Several MET inhibitors decreased DR4 levels in MET-amplified HCC827 cell lines resistant to EGFR-TKIs with no or limited effects on modulating DR5 levels, while increasing DR4 levels in HCC827 parental cells and other NSCLC cell lines. MET inhibitors did not affect DR4 stability, but decreased DR4 mRNA levels with suppression of AP-1-dependent DR4 promoter transactivation. Moreover, these inhibitors suppressed ERK and c-Jun phosphorylation accompanied with decreasing c-Jun levels. Hence, it is likely that MET inhibition downregulates DR4 expression in MET-amplified EGFR mutant NSCLC cells through suppressing AP-1-mediated DR4 transcription. Osimertinib combined with MET inhibition synergistically induces apoptosis in the MET-amplified EGFR mutant NSCLC cells accompanied with augmented DR4 reduction both in vitro and in vivo. Furthermore, MET inhibition combined with TRAIL enhanced killing of MET-amplified EGFR mutant HCC827/AR cells, but not HCC827 parental cells. These data collectively suggest that DR4 may possess an unrecognized anti-apoptotic function, contributing to apoptosis resistance under given conditions.

oncology

What problem does this paper attempt to address?

The problem this paper attempts to address is: How do MET inhibitors downregulate the expression of death receptor 4 (DR4) by inhibiting AP-1-mediated transcription, thereby overcoming MET amplification-induced acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Specifically, the researchers focus on the following points: 1. **MET Amplification and EGFR-TKI Resistance**: MET gene amplification is one of the important mechanisms of acquired resistance to first-generation EGFR-TKIs (such as erlotinib and gefitinib) and third-generation EGFR-TKIs (such as osimertinib) in NSCLC patients. 2. **Role of DR4 in Resistance**: DR4 is typically considered a death receptor that induces apoptosis by binding to TRAIL, but there are also reports that it may be involved in apoptosis resistance. The researchers found that MET inhibitors can reduce the expression of DR4, thereby enhancing the sensitivity of cells to apoptosis. 3. **Mechanism of Action of MET Inhibitors**: The researchers explored how MET inhibitors downregulate DR4 expression by inhibiting the MEK/ERK signaling pathway and AP-1-dependent DR4 transcription. 4. **Effect of Combination Therapy**: The researchers also evaluated the synergistic effect of combining MET inhibitors with EGFR-TKIs (such as osimertinib) or TRAIL to enhance the killing effect on MET-amplified NSCLC cells. Overall, this paper aims to reveal how MET inhibitors overcome acquired resistance to EGFR-TKIs in NSCLC by regulating DR4 expression and to provide a theoretical basis for developing new combination therapy strategies.

MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription

Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis

KLF4 Downregulates Htert Expression and Telomerase Activity to Inhibit Lung Carcinoma Growth.

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Abstract 5868: Upregulation of HER3 and MET in non-small cell lung cancer cells resistant to EGFR tyrosine kinase inhibitor

Abstract 6972: Programmed death-ligand 1 (PD-L1) upregulates c-MET phosphorylation via protein tyrosine phosphatase and contributes to the development of MET amplification in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer

Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells

Mutations in the MET Tyrosine Kinase Domain and Resistance to Tyrosine Kinase Inhibitors in Non-Small-cell Lung Cancer

Met Gene Amplification and Protein Hyperactivation is a Mechanism of Resistance to Both First and Third Generation EGFR Inhibitors in Lung Cancer Treatment

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

N 6 -methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments

Abstract 2105: C-Met Hyperactivation is an Universal Resistance Mechanism to Both First and Third Generation EGFR Inhibitors

MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways